• News
• Contact Us
• Home

Patent Portfolio

• Science & Technology
• OncoVAX® Treatment Schedule
• Scalable Production
• Patent Portfolio
• Science Due Diligence

Patent coverage for patient-specific tumor vaccines and Human Monoclonal Antibodies.

The Vaccinogen portfolio includes 20 approved or issued U.S. patents. The Company's patent estate covers any autologous tumor vaccine delivered with TICE BCG as an adjuvant, as well as tumor-specific antigens/epitopes, plus a broad portfolio of Human Monoclonal Antibodies including technology related to the use of those antibodies for imaging and for therapeutics.

Name	Number	Issued	Terminates
Active Specific Immunotherapy	U.S. 5,484,596	1/1996	2013*

This covers the entire OncoVAX® technology platform. It also includes the use of B-cells from immunized patients to create tumor-specific Human Monoclonal Antibodies.

U.S./EP Sterile Manufacturing

Being Issued

9/2007**

2025

This covers the entire OncoVAX® technology platform but emphasizes the manufacturing process that results in a sterile vaccine as mandated by the FDA.

Tumor Associated Epitopes	U.S. 951,985	9/1999	2016
The Antigen recognized by MCA 28A32	U.S. 5,521,285	5/1996	2013
Antigen recognized by MCA 16-88	U.S. 338,832	8/1994	2011
Tumor Associated Monoclonal Antibodies	U.S. 5,474,755	12/1995	2012

These patents disclose the methodology for making tumor-specific Human Monoclonal Antibodies from the B-cells of OncoVAX® immunized patients and describe the relevant epitopes (tumor associated antigens), which with the antibodies react. These Human Monoclonal Antibodies have been tested in radioimmunotherapy treatments (HumaRAD) and approved for use in Radioimmunodiagnostics (Humaspect). These are future products to be developed and commercialized by Vaccinogen.

In Vivo Binding Pair Pretargeting	U.S. 5,965,106	10/1999	2016
Site specific In Vivo activation of Therapeutic drugs	U.S. 5,433,955	7/1995	2012
Chelating Agents for attaching Metal Ions to proteins	U.S. 5,292,868	3/1994	2011

These patents cover the technology of targeting the Human Monoclonal Antibodies to the tumor and creating greater specificity. The cytotoxic agents such as radioisotopes are attached to the antibodies with either a unique chelating agent or by pretargeting. These methodologies will be applied to HumaRAD radiotherapy.

*	Can be extended to 2018 based on time delays caused by the FDA.
**	The patent has been reviewed and the claims that were allowed have been accepted. It is awaiting final allowance notification and patent number.